About Us
Innovative Drugs
Innovation Platform
News
Join Us
Contact Us
Keyword:
Latest News
VC005 Topical Gel is to Launch Phase III Trials! Jiangsu Vcare’s Fourth Independently Developed Innovative Drug will enter the Confirmatory Clinical Stage
Efficient Progress! Jiangsu Vcare Completed Patient Enrollment in Phase II Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor for Vitiligo
Crack the Challenge of Alopecia!Jiangsu Vcare Secures IND Approval in China for VC005 Tablets, a Next-Generation Selective JAK1 Inhibitor, in Alopecia Areata
Jiangsu Vcare Announces Positive Phase II Results for VC005 Topical Gel, a Second-Generation Highly Selective JAK1 Inhibitor, in the Treatment of Mild-to-Moderate Atopic Dermatitis (AD)
Jiangsu Vcare’s Next-Generation TRK Inhibitor Eratrectinib (VC004) Selected for the “SPARK Plan” for Pediatric Oncology Drugs
Jiangsu Vcare Announces First Patient Enrollment in Phase Ⅱ Clinical Trial of VC005 Tablets, a Second-Generation Highly Selective JAK1 Inhibitor, for Oral Treatment of Vitiligo